|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Escudier B, Porta C, Schmidinger M,
Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S and
Horwich A; ESMO Guidelines Committee. Electronic address, :
clinicalguidelines@esmo.org: Renal cell carcinoma: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 30:706–720. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaelin WG Jr: Molecular basis of the VHL
hereditary cancer syndrome. Nat Rev Cancer. 2:673–682. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Escudier B, Szczylik C, Porta C and Gore
M: Treatment selection in metastatic renal cell carcinoma: Expert
consensus. Nat Rev Clin Oncol. 9:327–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harshman LC, Xie W, Bjarnason GA, Knox JJ,
MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY,
et al: Conditional survival of patients with metastatic renal-cell
carcinoma treated with VEGF-targeted therapy: A population-based
study. Lancet Oncol. 13:927–935. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ficarra V, Novara G, Galfano A, Brunelli
M, Cavalleri S, Martignoni G and Artibani W: The ‘stage, size,
grade and necrosis’ score is more accurate than the University of
California los angeles integrated staging system for predicting
cancer-specific survival in patients with clear cell renal cell
carcinoma. BJU Int. 103:165–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI,
Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, et al: The
international metastatic renal cell Carcinoma database consortium
model as a prognostic tool in patients with metastatic renal cell
carcinoma previously treated with first-line targeted therapy: A
population-based study. Lancet Oncol. 16:293–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu L, Wang J, Kong W, Huang J, Dong B,
Huang Y, Xue W and Zhang J: LSD1 inhibition suppresses the growth
of clear cell renal cell carcinoma via upregulating P21 signaling.
Acta Pharm Sin B. 9:324–334. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liao Y, Xiao H, Cheng M and Fan X:
Bioinformatics analysis reveals biomarkers with cancer stem cell
characteristics in lung squamous cell carcinoma. Front Genet.
11:4272020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liao Y, Wang Y, Cheng M, Huang C and Fan
X: Weighted gene coexpression network analysis of features that
control cancer stem cells reveals prognostic biomarkers in lung
adenocarcinoma. Front Genet. 11:3112020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu L, Ding R, Zhang J, Zhang J and Lin Z:
Cyclin-dependent kinase 5 acts as a promising biomarker in clear
cell renal cell carcinoma. BMC Cancer. 19:6982019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ivan M, Kondo K, Yang H, Kim W, Valiando
J, Ohh M, Salic A, Asara JM, Lane WS and Kaelin WG Jr: HIFalpha
targeted for VHL-mediated destruction by proline hydroxylation:
Implications for O2 sensing. Science. 292:464–468. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hon WC, Wilson MI, Harlos K, Claridge TD,
Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI and
Jones EY: Structural basis for the recognition of hydroxyproline in
HIF-1 alpha by pVHL. Nature. 417:975–978. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cho H, Du X, Rizzi JP, Liberzon E,
Chakraborty AA, Gao W, Carvo I, Signoretti S, Bruick RK, Josey JA,
et al: On-target efficacy of a HIF-2α antagonist in preclinical
kidney cancer models. Nature. 539:107–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Wu T, Simon J, Takada M, Saito R,
Fan C, Liu XD, Jonasch E, Xie L, Chen X, et al: VHL substrate
transcription factor ZHX2 as an oncogenic driver in clear cell
renal cell carcinoma. Science. 361:290–295. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu L, Ding R, Yan H, Zhang J and Lin Z:
ZHX2 drives cell growth and migration via activating MEK/ERK signal
and induces sunitinib resistance by regulating the autophagy in
clear cell renal cell carcinoma. Cell Death Dis. 11:3372020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X, Simon JM, Xie H, Hu L, Wang J,
Zurlo G, Fan C, Ptacek TS, Herring L, Tan X, et al: Genome-wide
screening identifies SFMBT1 as an oncogenic driver in cancer with
VHL loss. Mol Cell. 77:1294–1306.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matos LL, Trufelli DC, de Matos MG and da
Silva Pinhal MA: Immunohistochemistry as an important tool in
biomarkers detection and clinical practice. Biomark Insights.
5:9–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bonasio R, Lecona E and Reinberg D: MBT
domain proteins in development and disease. Semin Cell Dev Biol.
21:221–230. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang M, Shen H, Jin Y, Lin T, Cai Q,
Pinard MA, Biswas S, Tran Q, Li G, Shenoy AK, et al: The malignant
brain tumor (MBT) domain protein SFMBT1 is an integral histone
reader subunit of the LSD1 demethylase complex for chromatin
association and epithelial-to-mesenchymal transition. J Biol Chem.
288:27680–27691. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawata H, Yamada K, Shou Z, Mizutani T,
Yazawa T, Yoshino M, Sekiguchi T, Kajitani T and Miyamoto K:
Zinc-fingers and homeoboxes (ZHX) 2, a novel member of the ZHX
family, functions as a transcriptional repressor. Biochem J.
373:747–757. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lv Z, Zhang M, Bi J, Xu F, Hu S and Wen J:
Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular
carcinoma. Am J Clin Pathol. 125:740–746. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagel S, Schneider B, Meyer C, Kaufmann M,
Drexler HG and Macleod RA: Transcriptional deregulation of homeobox
gene ZHX2 in Hodgkin lymphoma. Leuk Res. 36:646–655. 2012.
View Article : Google Scholar : PubMed/NCBI
|
